293 related articles for article (PubMed ID: 30506456)
1. A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study.
Touat M; Opatowski M; Brun-Buisson C; Cosker K; Guillemot D; Salomon J; Tuppin P; de Lagasnerie G; Watier L
Appl Health Econ Health Policy; 2019 Jun; 17(3):381-389. PubMed ID: 30506456
[TBL] [Abstract][Full Text] [Related]
2. Direct medical burden of antimicrobial-resistant healthcare-associated infections: empirical evidence from China.
Liu X; Cui D; Li H; Wang Q; Mao Z; Fang L; Ren N; Sun J
J Hosp Infect; 2020 Jun; 105(2):295-305. PubMed ID: 31931043
[TBL] [Abstract][Full Text] [Related]
3. Burden of Clostridium difficile Infections in French Hospitals in 2014 From the National Health Insurance Perspective.
Leblanc S; Blein C; Andremont A; Bandinelli PA; Galvain T
Infect Control Hosp Epidemiol; 2017 Aug; 38(8):906-911. PubMed ID: 28756805
[TBL] [Abstract][Full Text] [Related]
4. Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand.
Phodha T; Riewpaiboon A; Malathum K; Coyte PC
Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):305-312. PubMed ID: 30321493
[TBL] [Abstract][Full Text] [Related]
5. In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013.
Maroun R; Maunoury F; Benjamin L; Nachbaur G; Durand-Zaleski I
PLoS One; 2016; 11(9):e0162864. PubMed ID: 27649305
[TBL] [Abstract][Full Text] [Related]
6. Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.
Blein C; Gavazzi G; Paccalin M; Baptiste C; Berrut G; Vainchtock A
BMC Infect Dis; 2015 Aug; 15():350. PubMed ID: 26286598
[TBL] [Abstract][Full Text] [Related]
7. Costs and Outcomes of 1-year post-discharge care trajectories of patients admitted with infection due to antibiotic-resistant bacteria.
Touat M; Brun-Buisson C; Opatowski M; Salomon J; Guillemot D; Tuppin P; de Lagasnerie G; Watier L
J Infect; 2021 Mar; 82(3):339-345. PubMed ID: 33556428
[TBL] [Abstract][Full Text] [Related]
8. Healthcare-Associated Infections Due to Multidrug-Resistant Organisms: a Surveillance Study on Extra Hospital Stay and Direct Costs.
Giraldi G; Montesano M; Napoli C; Frati P; La Russa R; Santurro A; Scopetti M; Orsi GB
Curr Pharm Biotechnol; 2019; 20(8):643-652. PubMed ID: 30961489
[TBL] [Abstract][Full Text] [Related]
9. The incremental cost of infections associated with multidrug-resistant organisms in the inpatient hospital setting-A national estimate.
Johnston KJ; Thorpe KE; Jacob JT; Murphy DJ
Health Serv Res; 2019 Aug; 54(4):782-792. PubMed ID: 30864179
[TBL] [Abstract][Full Text] [Related]
10. The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective.
Iskandar K; Roques C; Hallit S; Husni-Samaha R; Dirani N; Rizk R; Abdo R; Yared Y; Matta M; Mostafa I; Matta R; Salameh P; Molinier L
BMC Infect Dis; 2021 May; 21(1):404. PubMed ID: 33933013
[TBL] [Abstract][Full Text] [Related]
11. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.
Roberts RR; Hota B; Ahmad I; Scott RD; Foster SD; Abbasi F; Schabowski S; Kampe LM; Ciavarella GG; Supino M; Naples J; Cordell R; Levy SB; Weinstein RA
Clin Infect Dis; 2009 Oct; 49(8):1175-84. PubMed ID: 19739972
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.
Keyloun KR; Weber DJ; Gardstein BM; Berger A; Gillard P; Ganz ML
Hosp Pract (1995); 2018 Dec; 46(5):278-286. PubMed ID: 30067108
[No Abstract] [Full Text] [Related]
13. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.
Le Monnier A; Duburcq A; Zahar JR; Corvec S; Guillard T; Cattoir V; Woerther PL; Fihman V; Lalande V; Jacquier H; Mizrahi A; Farfour E; Morand P; Marcadé G; Coulomb S; Torreton E; Fagnani F; Barbut F;
J Hosp Infect; 2015 Oct; 91(2):117-22. PubMed ID: 26253518
[TBL] [Abstract][Full Text] [Related]
14. Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.
Fukuda H; Yano T; Shimono N
Pharmacoeconomics; 2018 Nov; 36(11):1367-1376. PubMed ID: 30022364
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.
Classen DC; Pestotnik SL; Evans RS; Lloyd JF; Burke JP
JAMA; 1997 Jan 22-29; 277(4):301-6. PubMed ID: 9002492
[TBL] [Abstract][Full Text] [Related]
16. Using the best available data to estimate the cost of antimicrobial resistance: a systematic review.
Wozniak TM; Barnsbee L; Lee XJ; Pacella RE
Antimicrob Resist Infect Control; 2019; 8():26. PubMed ID: 30733860
[TBL] [Abstract][Full Text] [Related]
17. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.
Shrestha P; Cooper BS; Coast J; Oppong R; Do Thi Thuy N; Phodha T; Celhay O; Guerin PJ; Wertheim H; Lubell Y
Antimicrob Resist Infect Control; 2018; 7():98. PubMed ID: 30116525
[TBL] [Abstract][Full Text] [Related]
18. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs.
Kirkland KB; Briggs JP; Trivette SL; Wilkinson WE; Sexton DJ
Infect Control Hosp Epidemiol; 1999 Nov; 20(11):725-30. PubMed ID: 10580621
[TBL] [Abstract][Full Text] [Related]
19. Comparing methods to estimate incremental inpatient costs and length of stay due to methicillin-resistant Staphylococcus aureus in Alberta, Canada.
Kirwin E; Varughese M; Waldner D; Simmonds K; Joffe AM; Smith S
BMC Health Serv Res; 2019 Oct; 19(1):743. PubMed ID: 31651305
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of antibiotic resistance in China: a national level estimate for inpatients.
Zhen X; Stålsby Lundborg C; Sun X; Zhu N; Gu S; Dong H
Antimicrob Resist Infect Control; 2021 Jan; 10(1):5. PubMed ID: 33407856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
